A Prognosis and Predicting Genetic Study of Lung Cancer

Lung Cancer Clinical Trial

Official title:

A Prognosis and Predicting Genetic Study of Lung Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03234179
• Other study ID #: 201705110RIND
• Status: Not yet recruiting
• Phase: N/A
• First received: July 26, 2017
• Last updated: July 30, 2017
• Start date: August 1, 2017
• Est. completion date: August 1, 2037

Study information

• Verified date: July 2017
• Source: National Taiwan University Hospital
• Contact: Tung-Ming Tsai, MD
• Phone: +886972792011
• Email: eldorado0607[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Lung cancer is a leading cause of cancer mortality among adults worldwide. The incidence rates of lung cancer among never smoking females in some parts of East Asia are among the highest in the world. The adenocarcinoma of lung being the most frequently identified histological type is more weakly associated with smoking, and often occurs in females and never-smokers. Although family history of lung cancer has been associated with histological subtypes, the inherited susceptibility factors that affect specific histology are unknown.

Genetic factors that determine individual predisposition to lung cancer have been identified via genome-wide association studies. These known common loci, however, explain only a small fraction of the familial risk of lung cancer. The hypothesis of this study is that there are genetic factors that confer inherited susceptibility among patients with primary non-small-cell lung cancer (NSCLC).

Description:

To delineate the genetic etiology underlying NSCLC, this study proposes to employ a family-based linkage analysis, together with rich data generated from NGS, to search for disease susceptibility locus for the patients with strong family history of primary NSCLC. By using family pedigrees, linkage analysis will be able to find co-segregation of alleles through multiple generations at a genetic susceptibility locus and a known genetic marker, and then the highly penetrate gene loci may be detected by our study. These gene loci will be a good genetic predictor of NSCLC which should be a great advantage in treatment, prevention and screening of NSCLC in the future.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: August 1, 2037
• Est. primary completion date: August 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. The patient's family (within third-degree relatives) has at least one diagnosed of primary non-small cell lung cancer.

2. The patient was diagnosed of primary non-small cell lung cancer at the age < 45 years old.

Exclusion Criteria:

1. Patients without the diagnosis of primary non-small cell lung cancer.

2. Patients who are combined with other malignancy and ongoing chemotherapy / radiation therapy.

3. Patients combined with coagulopathy.

Related Conditions & MeSH terms

• Disease Susceptibility
• Genetic Predisposition to Disease
• Lung Cancer
• Lung Neoplasms

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Genetic information of lung cancer patients	Collect study subjects' blood sample and analysis with Genome-wide SNP genotyping	One week after the study subjects sign the permit of informed consents